| CATEGORY: AIM BULLETIN SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY |
Allergy's ragweed vaccine passes key trial |
|
Fri 24 Mar 2006
|
LONDON (SHARECAST) - Allergy Therapeutics received a boost today after the hay fever treatment outfit passed a key phase III clinical efficacy and safety trial for its ragweed allergy vaccine.
The initial results of the study demonstrated that Pollinex Quattro Ragweed was well tolerated and significantly reduced clinical symptoms compared with a placebo, said the group.
“The treatment schedule and speed of action of this ultra short course therapy should translate into rapid acceptance,” said Dr Piyush Patel, principle scientist for the study.
The Pollinex Quattro allergy vaccines, which require only four injections per year, have the potential to transform allergy treatment for the estimated 30m or more people in North America suffer from allergies to ragweed, the company added.
Allergy Therapeutics' R&D director Dr Tom Holdich said, “This is the climax of all the pre-phase III work that we have conducted over the last year and probably the most important data that we have generated in the last 5 years.”
“North America is now firmly in our sights. It's a fantastic shot in the arm.”
|
|
| |
|
 |
Front Page Stories |
 |
|
